- Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir
- Preclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household Transmission and to Minimize SARS-CoV-2 Rebound
- High Throughput Screen Identifies Non-Nucleoside Small Molecule Inhibitors of the SARS-CoV-2 RNA-Dependent RNA Polymerase
Enanta Pharmaceuticals To Present New Data For EDP-235 In Development As An Oral, Once-daily Treatment For Covid-19, At The International Conference On Antiviral Research
Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir
Preclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household
